peptide analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
=== Post-production === The filmmakers experimented with the visuals of Mega-City One, including the design and positioning of the city's tower blocks, to create the impression that the city had risen out of the remains of another. They found that replicating the comic visuals of blocks close together made the blocks appear small. Instead, they allowed more space between the buildings to emphasise the larger buildings and allow for the presence of roads and cars to allow for extrapolation outside of the picture. Outcrops and appendages were added to break up the buildings' straight lines. On 7 October 2011, the Los Angeles Times reported that Travis was prohibited from participating in the editing process following creative disagreements between producers and executives. Garland took over the editing process; his contribution was considered significant enough for him to seek a co-director credit—a situation considered unusual as Garland had never directed a film before and had not been in charge of any filming. The disagreement concerned a disapproval over the footage that Travis was providing. Although Travis was removed from the editing process, he was monitoring the progress of the film. On 10 October, Travis and Garland released a joint statement saying that they had agreed on an "unorthodox collaboration" before production began, that Travis was still involved in the film and that Garland was not seeking a co-director credit. In March 2018, Urban said that he believed Dredd should be considered Garland's directorial debut.
=== Laboratory automation === In research fields such as synthetic biology, where highly iterative experimentation is common, considerable efforts have been made to automate workflows. Digital microfluidics is often touted as a laboratory automation solution, with a number of advantages over alternative solutions such as pipetting robots and droplet microfluidics. These stated advantages often include a reduction in the required volume of experimental reagents, a reduction in the likelihood of contamination and cross-contamination, potential improvements in reproducibility, increased throughput, individual droplet addressability, and the ability to integrate with sensor and detector modules to perform end-to-end or even closed loop workflow automation.
Another study of the PfSPZ vaccine was published in December 2022, reporting vaccine efficacy at up to 48% at 6 months follow up, and up to 46% efficacy at 18 months. Recent field studies have evaluated PfSPZ Vaccine in malaria-experienced African adults. A randomized, double-blind, placebo-controlled trial in Burkina Faso tested a three-dose intravenous regimen and reported vaccine efficacy of up to 48% at 6 months and 46% at 18 months against naturally acquired Plasmodium falciparum infection. The vaccine was well tolerated and immunogenic in this population. Additional studies in Equatorial Guinea examined multi-dose priming regimens of PfSPZ Vaccine followed by controlled human malaria infection (CHMI). Several schedules were found to be safe and capable of inducing significant protection against homologous challenge. By 2022 more than twenty clinical trials of PfSPZ-based products had been completed or were ongoing across Africa, Europe and the United States. PfSPZ Vaccine has also been evaluated in women of childbearing age and in participants who later became pregnant. Two randomized, double-blind, placebo-controlled trials in Mali investigated vaccination following presumptive antimalarial treatment. Across two transmission seasons, vaccine efficacy against Plasmodium falciparum parasitaemia in women of childbearing age ranged from 41% to 61%, depending on dose and year of follow-up. Among participants who conceived after vaccination, the vaccine was safe for mothers and infants and reduced the incidence of malaria parasitaemia during pregnancy.
Sources: en.wikipedia.org
The N-terminal methionine usually found after translation has an N-terminus blocked with a formyl group. This formyl group (and sometimes the methionine residue itself, if followed by Gly or Ser) is removed by the enzyme deformylase. pyroglutamate
== External links == Calvete JJ (1995). "On the structure and function of platelet integrin alpha IIb beta 3, the fibrinogen receptor". Proc. Soc. Exp. Biol. Med. 208 (4): 346–60. doi:10.3181/00379727-208-43863a. PMID 7535429. Garner Stephen F., Campbell Kate, Metcalfe Paul, Keidan Jane, Huiskes Elly, Dong Jing-Fei, Lopez Jose A., Ouwehand Willem H. (2002). "Glycoprotein V: the predominant target antigen in gold-induced autoimmune thrombocytopenia" (PDF). Blood. 100 (1): 344–346. doi:10.1182/blood.V100.1.344. PMID 12070047.{{cite journal}}: CS1 maint: multiple names: authors list (link) Dumin J A, Dickeson S K, Stricker T P, Bhattacharyya-Pakrasi M, Roby J D, Santoro S A, Parks W C (2001). "Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen". J. Biol. Chem. 276 (31): 29368–74. doi:10.1074/jbc.M104179200. PMID 11359786.{{cite journal}}: CS1 maint: multiple names: authors list (link) http://www.reference.md/files/D019/mD019038.html Online Medical Dictionary, Platelet membrane glycoproteins Platelet+membrane+glycoproteins at the U.S. National Library of Medicine Medical Subject Headings (MeSH) http://www.ojrd.com/content/1/1/46/figure/F1?highres=y http://circ.ahajournals.org/content/99/1/e1/F4.large.jpg
==== Distribution ==== The volume of distribution of propranolol is about 4 L/kg or 320 L. The plasma protein binding of propranolol is approximately 90%, with a range of 85 to 96% in different studies. Propranolol is a highly lipophilic drug achieving high concentrations in the brain. The brain-to-blood ratio of propranolol in humans ranges from 15:1 to 33:1, whereas the ratio for the peripherally selective beta blocker atenolol has been found to be 0.2:1.
Sources: en.wikipedia.org
hydraulic skeleto-muscular apparatus of the feathers This functional component consists of the only of the structural features of the feather tracts, namely the cutis, and connective tissue layer fascia superficialis. This functional component was named "hydraulic skeletal" due to the fact that the fat bodies embedded within cutis and fascia act similar to the hydrostatic bodies within a hydrostatic skeleton. However the functional role of the fat bodies within the hydraulic skeleto-muscular apparatus of the feathers is to counteract forces generated by the erector and depressor muscle of the feathers tracts. rather than to facilitate movement within of a body.
== Isomers == Several isomers of Fumonisin B4 have been detected. A larger group is the partially hydrolysed form, denoted as PHFB4, which has been detected using HPLC-ITMS. Another significant isomer is the 3-epi-FB4, which has been identified using NMR, it has also been shown that this isomer occur 10-40% of the regular FB4 sample in nature.
By 1859, Cuba still did not have a Grand Lodge, and to accelerate this work, they contacted one of the most powerful figures of Freemasonry in the United States at the time, and today the most controversial figure in the history of North American Freemasonry, Albert Pike, requesting his guidance and assistance. Pike was at that time the Grand Commander of the Supreme Council of the Southern Jurisdiction of the United States for the Scottish Rite at Charleston, South Carolina.On March 26, 1859, Albert Pike gave his personal authority to the Cuban exile Andrés Cassard to create new offices, degrees, and bodies of the Scottish Rite in Cuba. However, later that year, Albert Pike and Albert Mackey also granted this authority to others in Cuba. Whether Cassard was aware of that is unclear. Four initiates from Fraternidad Lodge No. 387 joined three Cuban Freemasons living in Hudson, New York to formally petition the Grand Lodge of South Carolina to grant authority for a third Lodge. San Andres Lodge No. 93 was chartered in November 17, 1859. On November 27, 1859, the Grand Lodge of South Carolina granted a warrant to merge the three Cuban Lodges into the first Grand Lodge seen in Cuba in almost four decades; the Gran Logia de Colón (English: Grand Lodge of Columbus) at Santiago de Cuba. Under the authority Grand Lodge of Colon, the three Lodges were restructured as Fraternidad Lodge No.1, Prudencia Lodge No. 2, and San Andres Lodge No. 3. Francisco Griñán y Mozo served as the first Grand Master of the Grand Lodge of Colon.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.